Vanda Pharmaceuticals (VNDA)

$5.61 +0.11 (2.00%)
Market Cap 324.99M
Revenue (ttm) 198.77M
Net Income (ttm) -18.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9.51%
Debt to Equity Ratio 0.00
Volume 597,800
Avg Vol 484,328
Day's Range N/A - N/A
Shares Out 59.09M
Stochastic %K 76%
Beta 0.74
Analysts Sell
Price Target $12.67

Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 202 734 3400
Fax: 202 296 1450
Address:
2200 Pennsylvania Avenue NW, Suite 300E, Washington, United States
Texout
Texout Oct. 28 at 12:48 AM
$VNDA grossly mispriced, underappreciated and undervalued. Just randomly pick tickers as you like and see yourself. Say Crmd with a lot more shares outstanding at 2,6 x vandas value whilst showing a weaker balance sheet less cash at had and similar full year revenue projections… just reiterating that to me today’s fair value for Vanda, absent of any news or regulatory developments, should be sitting and fluctuating at 10-12$ not this ridiculous 5$ range. Holding for the inevitable correction. ( nothing against crmd just used as random reference)
0 · Reply
HFlier
HFlier Oct. 27 at 8:08 PM
$VNDA I use 9 different moving averages on my daily. They are now in a perfect bull stack 😀
1 · Reply
johnle66
johnle66 Oct. 27 at 4:48 PM
$VNDA 2 year high and more to come with earnings on Wednesday.
0 · Reply
Trendrebel
Trendrebel Oct. 27 at 4:29 PM
$VNDA You might hate or love this stock. But exactly at this level, you should not be a seller. Two topping tales are not confirmed. This should give a rapid spike short term, if we close above 5.63. If you are long term holder - ignore this.
1 · Reply
Trendrebel
Trendrebel Oct. 27 at 4:23 PM
$VNDA 52WK high here at 5.62. Might break out from here ( or go back and rest below 5.51 )
0 · Reply
mciuzelis
mciuzelis Oct. 27 at 2:41 PM
$OPK not every good company is a good stock for investment. Been w OPK since January. Despite active accumulation by insiders or even healthy a buy-back program, stock moved nowhere. Waste of time. Same goes with $VNDA, although I've still hodling here expecting positive news anytime soon. That being said last week cut my $OPK position in half and switched for $ASST. Seems it was a smart move as $ASST already gives me 100% profit. No regrets whatsoever of not switching all at once - just proved the theory of good Co / bad stock in a hard way.
0 · Reply
PicoPies
PicoPies Oct. 27 at 1:56 PM
$VNDA I think it will explode soon
0 · Reply
jacckkmm
jacckkmm Oct. 27 at 11:53 AM
$VNDA we could pound$6 later today …
0 · Reply
HFlier
HFlier Oct. 25 at 9:07 PM
$VNDA This stock is trading at a share price equal to cash on hand. That's crazy, it is right now worth at least $20.00 with no news even.
0 · Reply
Trendrebel
Trendrebel Oct. 25 at 7:19 AM
$VNDA Dear friends... Weekend charts ! A few comments: Positive list * Weekly gain * 3 of 4 trendlines ( 5.51 resistance ) confirmed broken * Close above Ext. Fib 100% Negative list * End the week with a topping tail ( strong reversal signal - if confirmed ) * End the week below exactly 0,01 below the 5.51 level Summasummarum: Even that the week was positive, it was not a happy ending ! Someone decided to dump +100K stocks at the very end, exactly to the level, we ( longs ) don´t like. It might result in selling pressure next week. If not - a strong bounce back to 6.23 is in the cards. But it´s incredible how loyal VNDA is to basic technical trading. I mentioned this already 3 years ago. It´s a small cap stock. It tells me, that inst. are very active here. Bottomline: We need som fundamental news to bring it to next level ( double digits ), otherwise it will wobble around this $5 level for a long time.
1 · Reply
Latest News on VNDA
Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

Oct 22, 2025, 4:30 PM EDT - 5 days ago

Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

Oct 8, 2025, 8:00 AM EDT - 19 days ago

Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

Oct 1, 2025, 5:02 PM EDT - 26 days ago

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"

Sep 25, 2025, 8:00 AM EDT - 4 weeks ago

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"

Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement

Aug 29, 2025, 3:21 PM EDT - 2 months ago

Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

Aug 28, 2025, 5:23 PM EDT - 2 months ago

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

Aug 28, 2025, 7:00 AM EDT - 2 months ago

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

Aug 21, 2025, 4:40 PM EDT - 2 months ago

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Aug 18, 2025, 7:00 AM EDT - 2 months ago

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:45 PM EDT - 3 months ago

Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 7:30 AM EDT - 3 months ago

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Jul 23, 2025, 4:45 PM EDT - 3 months ago

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

Jun 10, 2025, 8:00 AM EDT - 4 months ago

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

May 27, 2025, 9:00 AM EDT - 5 months ago

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

May 16, 2025, 5:30 PM EDT - 5 months ago

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:55 PM EDT - 6 months ago

Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call Transcript

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

May 7, 2025, 4:01 PM EDT - 6 months ago

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

May 5, 2025, 8:00 AM EDT - 6 months ago

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

May 2, 2025, 8:46 AM EDT - 6 months ago

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

Apr 23, 2025, 3:52 PM EDT - 6 months ago

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

Apr 7, 2025, 8:00 AM EDT - 7 months ago

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

Mar 31, 2025, 8:00 AM EDT - 7 months ago

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Feb 24, 2025, 7:00 AM EST - 8 months ago

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 10:29 PM EST - 9 months ago

Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 4:01 PM EST - 9 months ago

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Feb 5, 2025, 4:30 PM EST - 9 months ago

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

Jan 27, 2025, 7:00 AM EST - 9 months ago

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

Jan 8, 2025, 4:17 PM EST - 10 months ago

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity

Dec 20, 2024, 1:26 PM EST - 11 months ago

Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

Dec 20, 2024, 9:13 AM EST - 11 months ago

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.

Dec 16, 2024, 9:29 PM EST - 11 months ago

Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

Nov 12, 2024, 4:58 PM EST - 1 year ago

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:20 PM EST - 1 year ago

Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:02 PM EST - 1 year ago

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst

Nov 1, 2024, 2:05 PM EDT - 1 year ago

Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.

Oct 14, 2024, 10:56 AM EDT - 1 year ago

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.

Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals

Oct 14, 2024, 10:37 AM EDT - 1 year ago

Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals

Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share

Oct 14, 2024, 8:19 AM EDT - 1 year ago

Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share

Vanda Pharmaceuticals decries FDA's rejection of stomach paralysis drug as unjust

Sep 19, 2024, 3:17 PM EDT - 1 year ago

Vanda Pharmaceuticals decries FDA's rejection of stomach paralysis drug as unjust

Texout
Texout Oct. 28 at 12:48 AM
$VNDA grossly mispriced, underappreciated and undervalued. Just randomly pick tickers as you like and see yourself. Say Crmd with a lot more shares outstanding at 2,6 x vandas value whilst showing a weaker balance sheet less cash at had and similar full year revenue projections… just reiterating that to me today’s fair value for Vanda, absent of any news or regulatory developments, should be sitting and fluctuating at 10-12$ not this ridiculous 5$ range. Holding for the inevitable correction. ( nothing against crmd just used as random reference)
0 · Reply
HFlier
HFlier Oct. 27 at 8:08 PM
$VNDA I use 9 different moving averages on my daily. They are now in a perfect bull stack 😀
1 · Reply
johnle66
johnle66 Oct. 27 at 4:48 PM
$VNDA 2 year high and more to come with earnings on Wednesday.
0 · Reply
Trendrebel
Trendrebel Oct. 27 at 4:29 PM
$VNDA You might hate or love this stock. But exactly at this level, you should not be a seller. Two topping tales are not confirmed. This should give a rapid spike short term, if we close above 5.63. If you are long term holder - ignore this.
1 · Reply
Trendrebel
Trendrebel Oct. 27 at 4:23 PM
$VNDA 52WK high here at 5.62. Might break out from here ( or go back and rest below 5.51 )
0 · Reply
mciuzelis
mciuzelis Oct. 27 at 2:41 PM
$OPK not every good company is a good stock for investment. Been w OPK since January. Despite active accumulation by insiders or even healthy a buy-back program, stock moved nowhere. Waste of time. Same goes with $VNDA, although I've still hodling here expecting positive news anytime soon. That being said last week cut my $OPK position in half and switched for $ASST. Seems it was a smart move as $ASST already gives me 100% profit. No regrets whatsoever of not switching all at once - just proved the theory of good Co / bad stock in a hard way.
0 · Reply
PicoPies
PicoPies Oct. 27 at 1:56 PM
$VNDA I think it will explode soon
0 · Reply
jacckkmm
jacckkmm Oct. 27 at 11:53 AM
$VNDA we could pound$6 later today …
0 · Reply
HFlier
HFlier Oct. 25 at 9:07 PM
$VNDA This stock is trading at a share price equal to cash on hand. That's crazy, it is right now worth at least $20.00 with no news even.
0 · Reply
Trendrebel
Trendrebel Oct. 25 at 7:19 AM
$VNDA Dear friends... Weekend charts ! A few comments: Positive list * Weekly gain * 3 of 4 trendlines ( 5.51 resistance ) confirmed broken * Close above Ext. Fib 100% Negative list * End the week with a topping tail ( strong reversal signal - if confirmed ) * End the week below exactly 0,01 below the 5.51 level Summasummarum: Even that the week was positive, it was not a happy ending ! Someone decided to dump +100K stocks at the very end, exactly to the level, we ( longs ) don´t like. It might result in selling pressure next week. If not - a strong bounce back to 6.23 is in the cards. But it´s incredible how loyal VNDA is to basic technical trading. I mentioned this already 3 years ago. It´s a small cap stock. It tells me, that inst. are very active here. Bottomline: We need som fundamental news to bring it to next level ( double digits ), otherwise it will wobble around this $5 level for a long time.
1 · Reply
HFlier
HFlier Oct. 24 at 3:52 PM
$VNDA lol, some dick just dropped 12,000 shares at the start of a break out WTF?
0 · Reply
HornyUnicorn
HornyUnicorn Oct. 24 at 1:57 PM
$VNDA Gosh, I'd love to put money in here eventually. Just compare this to Swiss Idorsia Pharma stock, VNDA makes more money, more profit, less cashburn, more short term catalysts, less debt, more liquidity and valued 1/3 of Idorsia. The perfect somewhat de-risked stock.
1 · Reply
HFlier
HFlier Oct. 24 at 12:45 PM
$VNDA Market maker needs to tighten the spread on those options. They way it is makes it seem like a risky trade and that there is no demand for the options.
1 · Reply
HFlier
HFlier Oct. 24 at 12:40 PM
$VNDA Hey CEO, today of all days is the day to release some damn news - something, anything!
0 · Reply
BuyNow_SellLater
BuyNow_SellLater Oct. 24 at 12:05 AM
$VNDA nice little cup there
0 · Reply
Trendrebel
Trendrebel Oct. 23 at 4:31 PM
$VNDA Options actually very cheap
0 · Reply
jacckkmm
jacckkmm Oct. 23 at 1:26 PM
$VNDA fwiw
0 · Reply
HFlier
HFlier Oct. 22 at 9:25 PM
$VNDA They moved earnings date up about a week from previous bogey date. 😀
1 · Reply
mykhalifa
mykhalifa Oct. 22 at 8:36 PM
$VNDA this thing doesn’t move 😂
0 · Reply
HFlier
HFlier Oct. 22 at 11:58 AM
$VNDA Bull flagging on the daily.
0 · Reply
BioTechHealthX
BioTechHealthX Oct. 19 at 6:20 AM
$VNDA Analysts see Vanda Pharmaceuticals' shares surging to $20 from $5.10 as FDA collaboration signals regulatory turnaround. https://biotechhealthx.com/biotech-news/vanda-pharmaceuticals-vnda-targets-300-upside-with-breakthrough-fda-framework-deal/
0 · Reply
Trendrebel
Trendrebel Oct. 18 at 6:07 AM
$VNDA Fresh chart, my friends. It´s amazing how loyal ( and predictable ) the chart is. For 3 months now, we have been able to trade into the future ( just check my posts ). Last week, the chart told us heavy resistance around 5.51 ( 3 trendlines ). Logic move was a backtest to Inversed SHS neckline ( 5.11 ). And what happened... ? Made a topping tail ( strong reversal signal ) on 5.51. Direct back to test 5.11 - and rejected yesterday. So, what is in the crystal ball now ? I actually don´t need to tell you. BUT I can tell you, that the stock will go up 26% from the neckline, within the next 71 trading sessions ( evidence is in the reply ). I will add to my pos. coming weeks
2 · Reply